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Clinical outcomes after allogeneic hematopoietic stem cell transplantation (allo-SCT) from unrelated donors
(URDs) approach those of matched related donor (MRD) transplants in patients with acute myeloid leukemia
(AML). Yet, available data fail to account for differences in pretransplantation outcomes between these donor
selection strategies. In this regard, URD allo-HSCT is associated with longer waiting times to transplantation,
potentially resulting in higher probabilities of failure to reach transplant. We retrospectively analyzed 108 AML
patients accepted for first allo-HSCT from the time of approval to proceed to transplant. Fifty-eight (54%) patients
were initially allocated to MRD, while URD search was initiated in 50 (46%) patients. Time to transplant was longer
in patients allocated to a URD when compared with patients assigned to an MRD (median 142 days versus 100
days; p < .001). Forty-three of 58 (74%) patients in the MRD group and 35 of 50 (70%) patients in the URD group
underwent transplantation (odds ratio [OR], 1.22; p = .63). Advanced disease status at the time of allo-HSCT
approval was the only predictor of failure to reach transplantation in the multivariate analysis (OR, 4.78; p = .001).
Disease progression was the most common cause of failure to reach allo-HSCT (66.7%) in both the MRD and URD
groups. With a median follow-up from transplantation of 14.5 (interquartile range, 5 to 29) months, the 2-year
estimate of overall survival (OS) from allo-HSCT was 46% in the MRD group and 57% in the URD group (p = .54).
There were no differences in OS according to donor type allocation in the multivariate analysis (hazard ratio, 1.01;
p = .83). When including patients from the time of transplant approval, 2-year OS was 39% in the MRD group ver-
sus 42% in the URD group. Our study suggests that allocation of AML patients to URDs may result in comparable
clinical outcomes to MRD assignment without a significant increase in the risk of failure to reach transplant.
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Acute myeloid leukemia (AML) represents the most com-
mon indication for allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) worldwide [1]. Despite major
progresses in our understanding of AML biology and the recentarrival of emerging targeted therapies to the field, allo-HSCT
remains the first-choice consolidation strategy for fit patients
in first remission who are at a high risk of relapse [2,3,4]. More-
over, allo-HSCT is the only therapeutic option resulting in sig-
nificant long-term survival rates in patients with refractory or
relapsed disease [5]. Matched related donors (MRDs) offer the
best clinical outcomes and are thus the preferred graft source
in this setting, but about two thirds of the patients who require
a transplant will not have such a donor. Together with advan-
ces in conditioning regimens, graft-versus-host disease
(GVHD) prophylaxis, and supportive care, the growing use of
alternative donors has extended allo-HSCT eligibility in this
population of AML patients without an available MRD. While
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patients will currently find a potential donor, optimal alterna-
tive donor selection is still controversial.
A number of mainly retrospective studies have reported
outcomes after unrelated donor (URD) [6,7,8,9,10,11], haploi-
dentical [12,13], or umbilical cord blood (UCB) [14,15] trans-
plantation approaching those of MRD in adult patients with
AML, although with conflicting results with regard to the rela-
tive virtues and disadvantages of each alternative donor
source. Recent data from the European Society for Blood and
Marrow Transplantation showed a survival benefit for MRD,
fully matched URD or haploidentical allo-HSCT over UCB or
partially mismatched URD allo-HSCT [16]. Prior large observa-
tional studies have, on the other hand, reported comparable
overall survival (OS) after MRD, 8/8 HLA-matched URD
(MURD), and 7/8 mismatched URD (MMURD) allo-HSCT, albeit
at the expense of higher GVHD incidences in the latter 2
groups [9,11]. Single-center and registry data also suggest that
haploidentical transplantation with post-transplant cyclophos-
phamide prophylaxis may achieve similar OS and lower GVHD
incidence as compared with MURD transplants [12,13]. Like-
wise, UCB transplantation appears to provide similar outcomes
as those reported after MURD transplants in some studies
[14,15], as well as possibly lower relapse rates among patients
with positive pretransplant minimal residual disease [15].
Overall, significant between-study heterogeneity and the
inherent difficulties in isolating donor effects from the impact
of associated transplantation schemes have so far precluded
the definition of a definite hierarchy of alternative donor sour-
ces in patients with AML.
Notably, available data are restricted to those subsets of
patients who have successfully undergone transplantation and
therefore fail to account for differences in pretransplantation
outcomes between donor selection strategies. In this regard,
URD allo-HSCT is associated with limited donor availability for
patients who belong to ethnic minority groups and longer
waiting times to transplantation, potentially resulting in
higher probabilities of failure to reach transplantation and
poorer transplant outcomes [17,18,19]. Conversely, the near
universal and expedited access to haploidentical donors or
UCB units may favor these graft sources when short-lived
remission duration is expected or patient ethnicity predicts a
low a priori likelihood of finding a suitable URD. However, the
precise role of alternative donor selection on transplant rates
and pretransplant clinical outcomes remains speculative. In
this context, current practice is hence largely based on institu-
tional experience rather than on evidence-based approaches
to alternative donor selection.
In the present study we have evaluated the impact of donor
selection on both pretransplant and post-transplant clinical
outcomes based on a donor selection strategy consisting in the
preferential allocation of AML patients without MRD to MURD
or MMURD.
METHODS
Data Source and Patient Population
The study population included patients with AML who received approval
for first-time allo-HSCT at our institution between January 2011 and February
2017. Transplantation board meetings were held on a weekly basis. Trans-
plant approval refers to the specific date when the board issued a positive
decision regarding the indication of transplantation for any patient and,
accordingly, the acceptance of such a patient to proceed to allo-HSCT in our
HSCT unit. Patients with a frontline allo-HSCT indication were referred to the
transplantation board for allo-HSCT approval concomitantly with the admin-
istration of frontline chemotherapy. All these patients were administered at
least 1 cycle of consolidation chemotherapy before proceeding to transplant,
and a proportion of them received allo-HSCT approval before the assessment
of postinduction response (subsequently referred in the text as“transplantation approval at diagnosis”). Patients with advanced disease
were evaluated at the discretion of the referring physician, irrespective of dis-
ease status and planned treatment before allo-HSCT at the time of referral.
Those patients who did not fulfill standard criteria to undergo allo-HSCT
based on risk stratification according to international [2] and PETHEMA
Group recommendations, as well as those considered unfit for allo-HSCT after
evaluation by the transplantation board, were excluded from the analysis.
There were no patients denied to proceed to allo-HSCT approval due to medi-
cal insurance restrictions. Patients with acute promyelocytic leukemia were
excluded from the study. All patients consented to the use of their clinical
data and the study was approved by the Hospital Universitario Virgen del
Rocío Institutional Review Board. Data were retrospectively collected from
electronic records.
Donor Selection Algorithm
HLA typing of first-degree relatives was generally performed early after
the diagnosis of AML. Patients were assigned to receive an allo-HSCT from an
MRD if available. Nonsibling matched family donors were considered on an
individual basis. Search for URD was initiated in the remaining cases. When
not done before, high-resolution HLA-A, HLA-B, HLA-C, and DRB1 typing was
performed immediately after the confirmation of MRD unavailability. The pri-
mary donor choice was 8/8 allele matched URD for patients without an MRD,
with 7/8 matched URD being selected as a secondary choice. URD search was
not started until transplant approval, once confirmed that an MRD was not
available. Patients were assigned to search for a haploidentical donor if a suit-
able URD was not identified after a maximum of 4 months from the date of
search initiation.
Study Endpoints and Definitions
OS was measured separately from the date of approval to undergo allo-
HSCT and from the date of allo-HSCT. Relapse was defined as morphological
evidence of leukemia recurrence (bone marrow blasts 5%, reappearance of
blasts in the blood, or development of extramedullary disease). Relapse inci-
dence (RI) and leukemia-free survival (LFS) were calculated from the date of
transplant approval and from the date of allo-HSCT for patients in complete
remission (CR), with death without evidence of relapse or treatment failure
(relapse or death from any cause) as competing events, respectively. Patients
with active disease were included in the RI and LFS analyses from the date of
achievement of CR. Nonrelapse mortality (NRM) was calculated considering
relapse as a competing event. Acute GVHD (aGVHD) was graded using the
Glucksberg criteria [20]. Chronic GVHD (cGVHD) was evaluated according to
the National Institutes of Health consensus criteria [21]. Patients alive at day
100 were evaluable for cGVHD/late-onset aGVHD. aGVHD and cGVHD/late-
onset aGVHD incidences were estimated with death without aGVHD within
100 days or death without cGVHD/late-onset aGVHD as competing risks,
respectively. Genetic risk was assigned based on cytogenetic data and accord-
ing to the 2017 European LeukemiaNet risk stratification, with molecular data
(FLT3-ITD allelic ratio and/or NPM1 status) considered when available.
Statistical Analysis
The primary purpose of our analysis was the comparison of 2 donor allo-
cation strategies from the time of transplant approval. All comparisons
between patient groups were thus made based on the initial assignment to
donor type (MRD versus URD) at the time of inclusion into the allo-HSCT pro-
gram, irrespective of the final donor source in the patients that reached allo-
HSCT. Those patients that underwent haploidentical transplantation after
URD search failure were therefore included in the URD group. Standardized
mean differences (SMDs) were used as an effect size measure of differences
in baseline characteristics. Nonparametric cumulative incidences of allo-
HSCT from time of transplant approval were estimated for all patients
accepted into the program. A multivariate logistic regression model was fit-
ted to assess the impact of donor type assignment on the probabilities of
transplantation and to identify independent predictors of failure to reach
allo-HSCT after transplant approval. All variables with a p value <.2 on uni-
variate logistic regression analysis were evaluated in the multivariate analy-
sis. An interaction term was added to assess the potential effect modification
of donor assignment on the association between disease status and failure to
reach allo-HSCT. Probabilities of OS and LFS were estimated using the
Kaplan-Meier method. Nonparametric cumulative incidences were estimated
to assess RI, NRM, aGVHD, and cGVHD. Kaplan-Meier and cumulative inci-
dence curves were compared using the log-rank and the Gray tests, respec-
tively. Cox proportional hazards or Fine-Gray multivariate regression models
were constructed to estimate the effect of donor type assignment on clinical
outcomes. Reduced submodels were compared with reference models includ-
ing all the theoretically relevant covariates with a p value <.2 on univariate
analysis. The final models were selected based on the parsimonious principle
(ie, those with the minimum number of covariates and the lowest estimate
standard error, allowing for a 10% estimate change from the reference
model). Data management and statistical analyses were conducted in Stata
13 (StataCorp, College Station, TX) and R version 3.3.1 (www.r-project.org).
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Patient Baseline Characteristics
Baseline characteristics of the study population are summa-
rized in Table 1. Between January 2011 and February 2017, 108
eligible AML patients were accepted for first allo-HSCT at our
center. Fifty-eight (53.7%) patients were initially allocated to
MRDs, while URD search was initiated in 50 (46.3%) patients.
Median age at inclusion into the program was 47 (range, 17 to
68) years. Patients assigned to URDs were more likely to har-
bor adverse risk genetics (30.0% versus 19.0%; SMD = .31) and
to have advanced disease status at the time of transplant
approval (48.0% versus 32.6%; SMD = .52). Conversely, therapy-
related AML was more frequent among patients allocated to
MRD (13.8% versus 6.0%; SMD = .28).Predictors of Failure to Reach Transplantation and
Pretransplantation Clinical Outcomes
Probabilities to reach transplantation were similar irrespec-
tive of initial donor assignment status (Figure 1A). Forty-three
of 58 (74.1%) patients in the MRD group and 35 of 50 (70.0%)
patients in the URD group underwent transplantation (odds
ratio [OR] 1.22; 95% confidence interval [CI], .53 to 2.86;
p = .63). Patients with advanced disease at the time of allo-
HSCT approval were more likely to fail to reach transplantation
than those with early disease status (OR, 4.78; 95% CI, 1.94 to
11.78; p = .001) (Figure 1B), regardless of donor assignment
(for those with MRD: OR, 4.95 [95% CI, 1.42 to 17.31]; for those
allocated to URD search: OR, 4.65 [95% CI, 1.23 to 17.67]; p for
the interaction = .95). Twenty of 43 (46.5%) patients with
advanced disease (12 patients in partial remission [PR] or with
refractory/relapsed disease and 8 patients in CR1 after secondTable 1
Baseline Characteristics of Patients Accepted into the HSCT Program
Donor Type
Variable MRD (n = 58) URD (n = 50) SMD p
Age category .08 .91
17-39 yr 18 (31.0) 17 (34.0)
40-59 yr 33 (56.9) 28 (56.0)
60 yr 7 (12.1) 5 (10.0)
Sex .20 .30
Male 29 (50.0) 20 (40.0)
Female 29 (50.0) 30 (60.0)
Diagnosis .28 .56
De novo 35 (60.3) 33 (66.0)
Therapy-related 8 (13.8) 3 (6.0)
Pre-existing MDS/MPN or AML
with MRC
13 (22.4) 13 (26.0)
Not reported 2 (3.4) 1 (2.0)
Genetic risk category .31 .46
Favorable 6 (10.3) 7 (14.0)
Intermediate 33 (56.9) 23 (46.0)
Adverse 11 (19.0) 15 (30.0)
Not reported 8 (13.8) 5 (10.0)
Disease status at transplantation
approval
.52 .33
Transplantation approval at
diagnosis
11 (19.0) 11 (22.0)
CR1 (first-line treatment) 28 (48.3) 15 (30.0)
CR1 (second or later-line
treatment)
5 (8.6) 7 (14.0)
CR2 1 (1.7) 3 (6.0)
Partial response 2 (3.4) 2 (4.0)
Refractory disease 6 (10.3) 3 (6.0)
Relapsed disease 5 (8.6) 9 (18.0)
Values are n (%).
MDS indicates myelodysplastic syndrome; MPN, myeloproliferative neoplasm;
MRC, myelodysplasia-related changes.or further line treatment or CR2) failed to reach transplanta-
tion, as compared with only 10 of 65 (15.4%) among newly
diagnosed patients or those in CR1 after frontline chemother-
apy at the time of acceptance into the program. Age, sex, diag-
nosis (secondary versus de novo AML), and genetic risk
category were associated with the probability of transplanta-
tion. In multivariate analysis, advanced disease status at the
time of transplant approval remained as the only predictor of
failure to reach transplantation (OR, 4.52; 95% CI, 1.79 to
11.42; p = .001) (Table 2).
No interaction was detected between donor selection and
disease status in the final model (p = .89).
Time to transplant was significantly longer in patients allo-
cated to URDs when compared with patients assigned to MRD
(median 142 [IQR, 115 to 164] days versus 100 [IQR, 73 to 127]
days; p < .001). Reflecting the additional time required to com-
plete frontline chemotherapy, median time to transplant from
the date of transplant approval was 149 (IQR, 100 to 189) days
for patients included at diagnosis, as compared with 115 (IQR,
83 to 141) days for the rest of the patients (p = .03). The proba-
bility to reach allo-HSCT among subjects included at diagnosis
(81.8%) was similar to that of patients with early disease who
were included after achievement of CR1 (86.0%) (OR, .73; 95%
CI, .18 to 2.91; p = .66). Median times to exclusion from trans-
plant were 63 (IQR, 23 to 124) days and 113 (IQR, 63 to 163)
days for patients failing to reach allo-HSCT in the MRD and
URD cohorts, respectively (p = .47) (Figure 2).
Disease progression was the most common cause of failure
to reach allo-HSCT: 10 of 15 (66.7%) in both the MRD and URD
groups, while intercurrent complications from transplant
approval accounted for the remaining cases. By the time of fail-
ure to reach allo-HSCT, a suitable URD was available for 9
patients and donor search was still ongoing in 4 cases assigned
to URDs, whereas URD search had been unsuccessful for 2
patients (both of whom had available haploidentical donors).
Additionally, 4 AML relapses that did not ultimately preclude
transplantation were reported among newly diagnosed
patients or those in CR at the time of allo-HSCT approval (2 of
43 [4.7%] in the MRD group and 2 of 35 [5.7%] in the URD
group; p = .54).
Transplantation Characteristics
Seventy-eight eligible patients underwent a first allo-
HSCT during the study period. All 43 patients in the MRD
group received an HLA-identical sibling transplant. In the
URD group, 19 (54.3%) patients received an 8/8 matched
transplant, 14 (40.0%) were assigned to a 7/8 URD, and 2
(5.7%) patients underwent a haploidentical transplant after
URD search failure. The graft source was peripheral blood
stem cells in all MRD recipients, while 7 (20%) patients in the
URD group received a bone marrow transplant. Tacrolimus/
methotrexate was the first-choice immunoprophylactic regi-
men among those patients receiving myeloablative condi-
tioning, with antithymocyte globulin if receiving 7/8
matched URD. Tacrolimus/sirolimus was the GVHD prophy-
laxis most frequently used for those patients receiving
reduced-intensity conditioning. Other patient characteris-
tics are shown in Table 3.
Transplantation Outcomes
OS and LFS
With a median follow-up from transplantation of 14.5
(IQR, 5.4 to 28.5) months, the 2-year unadjusted estimate
of OS was 45.9% (95% CI, 29.8% to 60.6%) in the MRD group
and 57.1% (95% CI, 38.3% to 72.1%) in the URD group
Figure 1. Cumulative incidences of transplantation from the time of approval to proceed to transplant by (A) donor group allocation and (B) disease status at the time
of transplantation approval. Early disease refers to CR1 after frontline chemotherapy or transplantation approval at diagnosis, while advanced disease includes CR1
after second or further line treatment, >CR1, PR, or refractory/relapsed (R/R) disease.
Table 2
Predictors of Failure to Reach Transplantation
Univariate Multivariate
Variable OR p 95% CI OR p 95% CI,
Age Per 10-yr increase 1.27 .18 .90-1.80 1.01 .46 .98-1.05
Sex Male versus female .61 .26 .26-1.45 - - -
Diagnosis Secondary* versus de novo 1.11 .82 .45-2.76 - - -
Genetic risk category Adverse versus favorable/intermediate .80 .54 .39-1.63 - - -
Disease status at HSCT approval Advanced versus early diseasey 4.78 .001 1.94-11.78 4.52 .001 1.79-11.42
Donor type assignment URD versus MRD 1.22 .63 .53-2.86 .97 .95 .39-2.41
R/R indicates refractory/relapsed.
* Therapy-related AML, AML with MRC, or MPN-AML.
y Early disease: CR1 after frontline chemotherapy or HSCT approval at diagnosis; advanced disease: CR1 after second or further line treatment, >CR1, PR, or R/R
disease.
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was 46.8% (95% CI, 30.9% to 61.3%) in the MRD group and
55.0% (95% CI, 35.8% to 70.7%) in the URD group
(Figure 3B). There were no differences in OS (hazard ratio
[HR], 1.01; 95% CI, .54 to 2.16; p = .83) or LFS (HR, .92; 95%
CI, .46 to 1.86; p = .83) in the multivariate analysis (Table 4).
When including patients from the time of transplant
approval, 2-year OS was 38.9% (95% CI, 26.3% to 51.3%) in
the MRD group versus 42.3% (95% CI, 28.2% to 55.7%) in the
URD group, while 2-year LFS was 46.1% (95% CI, 30.5% to
60.4%) in the MRD group and 49.0% (95% CI, 32.5% to 63.6%)
in the URD group) (Figures 4A and 4B).
RI and NRM
The 2-year unadjusted estimate of RI was 34.9% (95% CI,
20.2% to 50.0%) in the MRD group and 16.3% (95% CI, 5.7%
to 31.8%) in the URD group (Figure 3C), while the 2-year
unadjusted estimate of NRM was 21.5% (95% CI, 10.5% to
35.2%) in the MRD group and 30.8% (95% CI, 15.7% to 47.3%)
in the URD group (Figure 3D). In the multivariate analysis
there was a lower risk of relapse in the URD group (subdis-
tribution HR [sHR], .26; 95% CI, .07 to .91; p = .04), accom-
panied by a significant increase in the risk of NRM (sHR,
2.85; 95% CI, 1.04 to 7.80; p = .04) (Table 4). Differences in
2-year RI were abrogated when the analysis was performed
from the time of transplant approval (36.0% [95% CI, 21.4%
to 50.8%] in the MRD group and 28.0 [95% CI, 14.8% to
42.8%] in the URD group) (Figure 4C).Graft-versus-Host Disease
The unadjusted cumulative incidence of grade II to IV
aGVHD was 35.7% (95% CI, 20.9% to 50.7%) in the MRD group
and 50.1% (95% CI, 32.1% to 65.8%) in the URD group
(Figure 3E). The risk of grade III or IV aGVHD was similar in
both groups (18.6% [95% CI, 8.6% to 31.6%] in the MRD group
and 20.0% [95% CI, 8.7% to 34.7%] in the URD group). Regarding
cGVHD, the 2-year unadjusted cumulative incidence (including
3 late-onset aGVHD events) did not differ significantly
between the MRD group (47.0% [95% CI, 28.9% to 63.2%] and
the URD group (39.7% [95% CI, 21.9% to 56.9%]) (Figure 3F). The
risks of grade II to IV aGVHD (sHR, 1.56; 95% CI, .78 to 3.13; p =
.21) and cGVHD (sHR, .84; 95% CI, .37 to 1.87; p = .66) were
similar in both groups in the multivariate analysis.
Outcomes in the subgroup analysis of recipients of 8/8 or 7/
8 matched URD transplantation are shown in the supplemen-
tary material (Supplementary Table S1 and Supplementary
Figure S1).
DISCUSSION
A number of studies have analyzed the advantages and
disadvantages of the different alternative donor sources for
adult AML patients without an MRD. While URD, haploi-
dentical and UCB transplantation may lead to similar clini-
cal outcomes, waiting times to transplantation vary
significantly between graft sources. In fact, delays associ-
ated to URD search have been cited among the reasons that
may justify the preferential use of other alternative donors
Figure 2. Cumulative incidences of failure to reach transplantation from the
time of approval to proceed to transplant by donor group allocation.
Table 3
Characteristics of Patients who Underwent Transplantation
Donor Type SMD p
Variable MRD (n = 43) URD (n = 35)
Age category .22 .74
17-39 yr 14 (32.6) 13 (37.1)
40-59 yr 24 (55.8) 20 (57.1)
60 yr 5 (11.6) 2 (5.7)
Sex .11 .63
Male 22 (51.2) 16 (45.7)
Female 21 (48.8) 19 (54.3)
Diagnosis .31 .42
De novo 28 (65.1) 23 (65.7)
Therapy-related 6 (14.0) 2 (5.7)
Pre-existing MDS/MPN or
AML with MRC
9 (20.9) 10 (28.6)
Genetic risk category .50 .20
Favorable 4 (9.3) 4 (11.4)
Intermediate 27 (62.8) 14 (40.0)
Adverse 7 (16.3) 12 (34.3)
Not reported 5 (11.6) 5 (14.3)
Disease status at transplantation
approval
.64 .06
CR1 with negative MiRD 28 (65.1) 20 (57.1)
CR1 with positive MiRD 7 (16.3) 3 (8.6)
CR2 2 (4.7) 9 (25.7)
Refractory or relapsed disease 6 (14.0) 3 (8.6)
HCT comorbidity index .12 .97
Low 9 (20.9) 6 (17.1)
Intermediate 14 (32.6) 12 (34.3)
High 17 (39.5) 15 (42.9)
Not reported 3 (7.0) 2 (5.7)
Conditioning regimen .14 .55
Myeloablative 25 (58.1) 18 (51.4)
Reduced intensity 18 (41.9) 17 (48.6)
Donor type - -
HLA-matched sibling 43 (100) 0
Unrelated donor (8/8) 0 19 (54.3)
Unrelated donor (7/8) 0 14 (40.0)
Haploidentical 0 2 (5.7)
Stem cell source .71 .003
Peripheral blood 43 (100) 28 (80.0)
Bone marrow 0 7 (20.0)
GVHD prophylaxis* - -
CNI/methotrexate 32 (74.4) 8 (22.9)
CNI/methotrexate/antithymocyte
globulin
0 8 (22.9)
Tacrolimus/sirolimus 11 (25.6) 16 (45.7)
Other 0 3 (8.6)
Recipient/donor CMV match .93 .002
Pos/pos 33 (76.2) 14 (43.6)
Pos/neg 6 (14.3) 14 (38.5)
Neg/pos 0 2 (5.1)
Neg/neg 0 2 (5.1)
Not reported 4 (9.5) 3 (7.7)
Recipient/donor sex match .76 .02
Male/male 11 (25.6) 14 (40.0)
Male/female 11 (25.6) 2 (5.7)
Female/male 12 (27.9) 16 (45.7)
Female/female 9 (20.9) 3 (8.6)
Values are n (%).
MiRD indicates minimal residual disease; HCT, hematopoietic cell transplanta-
tion; CNI, calcineurin inhibitor; CMV, cytomegalovirus; pos, positive; neg,
negative.
*Group comparison is not shown as GVHD prophylaxis schemes differ by
protocol according to donor source.
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transplantation by donor type assignment have not been
taken into consideration in previous analyses. To our best
knowledge, this study represents the first attempt to com-
pare outcomes from the time of allo-HSCT approval
between 2 different donor allocation strategies, MRD and
URD, in patients with AML.
In our series, 27% of patients receiving approval to
undergo allo-HSCT could not reach transplant due to either
disease progression or onset of other disease-related com-
plications. This finding is in line with the pretransplantation
attrition rate reported among high-risk patients selected for
allo-HSCT in the German-Austrian AMLHD98A trial [10]. As
expected, URD allocation was associated with a 42-day
increase in median time to transplant with respect to MRD
assignment. Despite this substantial delay, a similar propor-
tion of patients were able to proceed to allo-HSCT after
assignment to either group in our cohort. Advanced disease
at the time of the approval of transplant indication emerged
as a major predictor of failure to reach transplant in our
analysis, while no association was found for other baseline
characteristics, including type of donor.
Disease relapse or refractoriness to treatment was the
primary driver of failure to reach allo-HSCT among the
patients included in the study, accounting for 70% of cases.
URD search failure was a rare event on the other hand,
being reported in just 2 patients. Disease progression and
other complications impeding allo-HSCT often occurred
early after the approval of the transplant indication.
Median time to proceed to allo-HSCT was 120 days, while
median time to exit from the transplantation program was
just 89 days. This pattern of early failures may partly
explain the lack of impact of donor type allocation on trans-
plantation rates despite the significant delays associated
with URD search.
There were no detectable differences with regards to
transplantation outcomes in 2-year OS or LFS estimates
between donor type groups. In contrast, a significantly lower
2-year RI was counterbalanced by an increased 2-year NRM
in the URD group. These results were upheld in subsequent
multivariate analyses. Taken together, these data are largely
consistent with previous reports showing comparable out-
comes after MRD or URD transplantation [611]. Moreover,no significant differences in terms of survival or relapse rates
were observed upon analyzing outcomes from the time of
transplant approval.
Our analysis has several limitations. First, the sample size
of the study compromised our ability to perform in-depth
Figure 3. Clinical outcomes from the time of transplant by donor type assignment: (A) OS, (B) LFS, (C) RI, (D) NRM, (E) grade II to IV aGVHD, and (F) cGVHD. Log-rank
or Gray's p values are shown.
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explore whether allocation to URDs may lead to lower trans-
plantation rates in specific patient subpopulations. Although
we did not find an interaction between disease status at the
time of allo-HSCT approval and donor type assignment,
these results require replication in larger studies. For similar
reasons, we could not formally compare outcomes between
MURD and MMURD recipients. A rough comparison between
groups indicates, however, that MMURD allo-HSCT did notresult in inferior clinical outcomes in our cohort. Second, the
homogenous ethnic composition of our patient population
of primarily Caucasian descent limits the generalizability of
our conclusions. Analyses based on the U.S. National Marrow
Donor Program data estimate that the likelihoods of finding
an 8/8 or a 7/8 URD may be as low as 18% and 71% among
sub-Saharan Africans, as compared with probabilities of 75%
and 97%, respectively, for Caucasians [17]. The potential
impact of ethnicity on transplantation rates and whether
Table 4
Multivariate Regression Analysis of Transplantation Clinical Outcomes by
Donor Type
Outcome (s)HR (95% CI) p
OS .83
MRD 1
URD 1.01
(.54-2.16)
LFS .83
MRD 1
URD .92
(.46-1.86)
RI .04
MRD 1
URD .26
(.07-.91)
NRM .04
MRD 1
URD 2.85
(1.04-7.80)
Grade II-IV aGVHD .21
MRD 1
URD 1.56
(.78-3.13)
cGVHD .66
MRD 1
URD .84
(.37-1.87)
OS and LFS were adjusted for disease status at transplantation; RI was adjusted
for diagnosis (de novo versus secondary AML) and genetic risk category; NRM
was adjusted for disease status at transplantation and CMV mismatch; cGVHD
was adjusted for the HCT comorbidity index; no additional covariates were
selected to be included in the final model for grade II to IV aGVHD.
Figure 4. Clinical outcomes from the time of transplant approval by donor
type assignment. (A) OS, (B) LFS, and (C) RI. Log-rank or Gray's p values are
shown.
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early allocation to haploidentical or UCB transplants rather
than to URDs search remain key questions that could not be
addressed in the present study. Third, waiting times from
the time of approval to proceed to transplant are dependent
on the efficiency of transplantation programs and differ
across health systems and institutions. Thus, the degree to
which our data can be extrapolated to other settings needs
to be further examined. In this regard, the median time to
identify an available URD in the experience of the REDMO
(Registro Espa~nol de Donantes de Medula Osea) was 37
(range, 32 to 51) days during the study period, with a
reported 80% probability of finding a suitable donor in the
first 3 months since the start of the search. Finally, these
results may not apply to diagnoses other than AML. In this
respect, considering that most patients with AML who are
candidates to receive an allo-HSCT can be identified as early
as at the time of diagnosis or at the time of disease response
evaluation after first induction therapy, the 42-day median
delay to proceed to transplant between patients assigned to
URDs as compared with MRD allocation had no impact on
the probability to reach allo-HSCT. This might not be the
case in other clinical scenarios where the transplant indica-
tion cannot be anticipated. For instance, even within AML,
patients may not be considered candidates to proceed to
transplantation a priori but later in the disease course due to
poor response to treatment.
Notwithstanding these limitations, our study indicates
that allocation of AML patients to URDs may result in com-
parable clinical outcomes to MRD assignment without an
associated increased risk of failure to proceed to transplant.
Overall, these data highlight the need for integration of
both pretransplantation and post-transplantation data in
future studies evaluating donor selection strategies inpatients undergoing allo-HSCT. Further validation of these
results and comparison with outcomes obtained with other
alternative graft sources are warranted.
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